FUCA1 and cancer: Among these potential targets of USP35, we would like to specifically focus on α-L-fucosidase 1 (FUCA1) in our current study (Figs. 3B and S5B, C), considering the strong relevance of altered glycosylation in cancer development and therapeutics [24].